SCHEMBL857997

SCHEMBL857997

COc1c(Br)ccc2c(Cl)ncnc12

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 9/20 0.44
ALDH1A1 P00352 3/20 0.42
NQO2 P16083 1/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
PDE1B Q01064 4/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1C Q14123 1/20 0.37
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL857052 0.81 PDE1B (0.54) PDE5AALDH1A1HPGDLMNAKDM4E
SCHEMBL30605542 0.81 PDE1B (0.54) PDE5AALDH1A1HPGDLMNAKDM4E
SCHEMBL17142264 0.77 ALDH1A1 (0.43) PDE5AALDH1A1HPGDLMNAKDM4E
SCHEMBL856422 0.76 PDE5A (0.68) PDE5AALDH1A1PDE1BMEN1KMT2A
Hydrochloric Acid SCHEMBL6786207 0.75 PDE5A (0.66) PDE5AALDH1A1PDE1BMEN1KMT2A
SCHEMBL28501805 0.74 ALDH1A1 (0.37) ALDH1A1HPGDLMNAKDM4EKMT2A
SCHEMBL857392 0.74 ALDH1A1 (0.53) PDE5AALDH1A1HPGDLMNAKDM4E
SCHEMBL17142295 0.72 ALDH1A1 (0.45) PDE5AALDH1A1HPGDLMNAKDM4E
SCHEMBL26998839 0.72 NQO2 (0.44) PDE5AALDH1A1NQO2KDM4EPOLB
SCHEMBL31728793 0.71 KDM4E (0.49) PDE5AALDH1A1HPGDLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDE5A 1611/4885ALDH1A1 3395/4885NQO2 1090/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDE5A 1481/4885ALDH1A1 3533/4885NQO2 1468/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDE5A 1359/4885ALDH1A1 3049/4885NQO2 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.